BioMarin Pharmaceutical Inc.
BMRN
Positions held
Your positionsBMRN isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- BioMarin Pharmaceutical Inc. operates in the biotechnology sector, which is characterized by high growth potential and innovation, particularly in rare disease treatments.
- Revenue increased by 29% compared to the prior quarter, reaching $990 million.
- Gross margin improved to 79.5%, up from 74.6% in the previous quarter.
- The company has a high trailing P/E ratio of 151.95, indicating potential overvaluation relative to earnings.
- Net income decreased significantly to $44.762 million in Q2 2026, down from $105.527 million in Q1 2026.
- The score indicates a 'Strong Sell' with a score of -16.00, reflecting negative trends in key indicators.
Fundamentals
| Market cap | $10.63B | Enterprise value | $13.95B | Trailing P/E | 148.35 | Forward P/E | 8.28 |
| PEG | 0.32 | Price / book | 1.68 | Beta | 0.22 | Dividend yield | 0.00% |
| Revenue growth | 19.9% | Earnings growth | -81.3% | Gross margin | 51.0% | Operating margin | 21.2% |
| Profit margin | 2.1% | ROE | 1.2% | ROA | 3.3% | Debt / equity | 0.66 |
| Current ratio | 2.39 | Free cash flow | $85.16M | Analyst recommendation | buy | Mean target | $91.62 |
| 52w high | $70.98 | 52w low | $49.26 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $990M | $766M | $875M | $776M | $825M | — |
| Op margin | 11.2% | 16.9% | -5.1% | -6.0% | 33.5% | — |
| Net income | $44.8M | $106M | -$46.6M | -$30.7M | $241M | — |
| Gross margin | 79.5% | 74.6% | 68.5% | 82.0% | 81.8% | — |
| Gross profit | $787M | $571M | $599M | $636M | $675M | — |
| Operating income | $111M | $130M | -$44.6M | -$46.7M | $277M | — |
- Revenue +29% vs prior quarter ($990M vs $766M).
- Gross margin 79.5% (was 74.6% prior quarter).
- Operating margin compressed to 11.2%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $3.2B | $2.9B | $2.4B | $2.1B | — |
| Op margin | 12.7% | 16.6% | 7.7% | 2.7% | — |
| Net income | $349M | $427M | $168M | $142M | — |
| Gross margin | 77.7% | 79.7% | 78.0% | 76.0% | — |
| Gross profit | $2.5B | $2.3B | $1.9B | $1.6B | — |
| Operating income | $409M | $474M | $186M | $57.4M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · BioMarin Pharmaceutical (BMRN), What Is Behind The Latest Attention?
2026-10-07 · FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing
2026-10-06 · BioMarin Expects Pre-tax Charges Related to Alesta Acquisition to Impact Q3 Adjusted EPS
2026-10-05 · BioMarin Appoints Cara Bauer as Chief People Officer
2026-10-02 · BioMarin Says 5-Year Data Shows Durable Efficacy of Pombiliti Plus Opfolda in Pompe Disease
2026-10-01 · The Strategic Financial Case for BioMarin Pharmaceutical (BMRN)
2026-10-01 · BioMarin and Profluent partner on AI-designed enzyme therapies
2026-10-01 · BioMarin and Profluent partner on AI-designed enzyme therapies
2026-09-30 · Profluent Partners With BioMarin to Design Novel Medicines Using AI
2026-09-28 · 3 Healthcare Stocks That Fall Short
2026-09-21 · Travere Therapeutics Announces Planned Chief Executive Officer Transition
Price (daily)
Full chart · RSI · MACD · patterns